ATRIUM HEALTH, WAKE FOREST BAPTIST HEALTH, WAKE FOREST SCHOOL OF MEDICINE AND RENALYTIX PARTNER TO ADVANCE KIDNEY HEALTH Partnership marks a long-term commitment to reducing impact of kidney disease in large populations via integration of earlier risk assessment paired with comprehensive disease management NEW YORK, CHARLOTTE AND WINSTON-SALEM, N.C., May, 19 2021 Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), Atrium Health, Wake Forest Baptist Health and Wake Forest School of Medicine announced a partnership to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The KidneyIntelX bioprognostic platform for early-stage diabetic kidney disease risk assessment will be available through Atrium Health s electronic health record (EHR) system, providing acces
Share this article
Share this article
CHARLOTTE, N.C., Jan. 28, 2021 /PRNewswire/ The unique public-private partnership spearheaded by Honeywell, Atrium Health, Tepper Sports & Entertainment and Charlotte Motor Speedway is launching a mass vaccination program over the next three days at Bank of America Stadium, home of the Carolina Panthers and Charlotte Football Club. The effort brings together each organization s unique strengths in logistics, healthcare and managing large events, to vaccinate as many area residents as quickly as possible.
The mass vaccination event at Bank of America Stadium, is anticipated to administer approximately 19,000 first dose vaccines over the three-day period, serving both drive-up and walk-up traffic, from Fri., Jan. 29 to Sun., Jan. 31. It s one of the largest vaccination sites in the country and the largest in North Carolina, based on anticipated patient throughput. There are no out-of-pocket costs for patients to receive the vaccine.
Share this article
Share this article
CHARLOTTE, N.C., Jan. 14, 2021 /PRNewswire/ Honeywell, Atrium Health, Tepper Sports & Entertainment and the Charlotte Motor Speedway have announced a unique public-private partnership with the State of North Carolina, and backed by Gov. Roy Cooper, to support the goal of 1 million COVID-19 vaccinations by July 4, 2021. In collaboration with the North Carolina Department of Health and Human Services (DHHS), the City of Charlotte and Mecklenburg County, these organizations aim to unleash their combined strength to vaccinate as many frontline workers, members of the general public and of underserved communities as quickly and efficiently as possible.
SISCO’) study.
1 The results from 30 patients treated with siltuximab in the ‘SISCO’ study compared with 30 matched controls, showed that treatment with siltuximab led to a 54% reduction
in risk of 30-day all-cause mortality.
2
This pivotal study will evaluate the efficacy and safety of standard of care (SOC) with or without intravenous siltuximab in selected hospitalised patients with COVID-19 previously treated with corticosteroids or another respiratory virus infection. Unlike previous studies of agents targeting the interleukin-6 (IL-6) signalling pathway, the ‘SILVAR’ study has been rationally designed to only enrol those hospitalised patients suffering from serious viral acute respiratory distress syndrome (ARDS) in a hyperinflammatory state that will most likely benefit from the addition of an anti-IL-6 immunomodulator such as siltuximab.